A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Status: Recruiting
Location: See all (6) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
A Phase 1/1B Study of ST-01156 in Patients with Advanced Solid Malignancies
Eligibility
Participation Requirements
Sex: All
Minimum Age: 16
Healthy Volunteers: f
View:
• Age ≥ 18 years on the day of signing the consent form, except for adolescents with Ewing Sarcoma or other malignancies for which there is a biological rationale to support participation, in which case the participant is ≥ 16 years old.
• Has a metastatic or locally advanced and unresectable solid tumor.
• Has at least 1 measurable lesion or evaluable disease per RECIST v1.1.
• Has an ECOG performance status ≤ 2 at screening.
• Has adequate organ function as defined in the protocol.
Locations
United States
California
The City of Hope National Medical Center
NOT_YET_RECRUITING
Duarte
Hoag Memorial Hospital
RECRUITING
Newport Beach
Massachusetts
Dana Farber Cancer Institute
NOT_YET_RECRUITING
Boston
Mass General Brigham Cancer Institute
NOT_YET_RECRUITING
Boston
New York
Memorial Sloan Kettering Cancer Center
NOT_YET_RECRUITING
New York
Texas
The University of Texas MD Anderson Cancer Center
NOT_YET_RECRUITING
Houston
Contact Information
Primary
Dr. Eric Rowinsky Chief Medical Officer
erowinsky@oncodrugs.com
(908) 883-0647
Time Frame
Start Date: 2025-12-01
Estimated Completion Date: 2029-12-31
Participants
Target number of participants: 171
Treatments
Experimental: Dose Escalation
ST-01156, administered orally once daily for 5 consecutive days followed by 2 days without study drug administration every 7 days
Related Therapeutic Areas
Sponsors
Leads: SEED Therapeutics, Inc.